Enclomiphene as a Telehealth Product
Fertility-Preserving SERM, Used Off-Label for Hypogonadism
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not FDA-approved for hypogonadism; prescribed and compounded off-label
Reference only. Not medical advice.
What can go wrong
Off-label use means efficacy and safety for hypogonadism are not FDA-reviewed. Reported considerations include mood changes and visual disturbances (a clomiphene-class effect), and the need to monitor estradiol and testosterone. Compounded products carry potency and purity variability.
This is something to take to a clinician. The Atlas can tell you what is known about enclomiphene as a telehealth product in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Enclomiphene is a selective estrogen receptor modulator (SERM), the trans-isomer of clomiphene, that blocks estrogen feedback at the hypothalamus and pituitary, increasing LH and FSH and thereby raising the body's own testosterone. Because it stimulates rather than replaces endogenous production, it generally preserves fertility, the key marketing advantage over exogenous TRT. It is not FDA-approved for hypogonadism, so telehealth platforms (notably Maximus, Hims) prescribe it off-label, often via compounding pharmacies.
The telehealth answer to 'TRT without losing fertility.'
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
By blocking estrogen receptors at the hypothalamus and pituitary, enclomiphene removes negative feedback, increasing GnRH-driven LH and FSH secretion. This stimulates the testes to produce more testosterone and supports spermatogenesis, unlike exogenous testosterone, which shuts the axis down.
Enclomiphene citrate is the purified trans-isomer of clomiphene citrate (which is a mix of enclomiphene and zuclomiphene); isolating the trans-isomer is intended to reduce certain estrogenic side effects.
Why platforms favor it
Enclomiphene lets a platform offer a 'testosterone' product that preserves fertility and avoids the controlled-substance status of testosterone itself. But it is off-label for hypogonadism, frequently compounded (variable potency/quality), and lacks the long-term safety dataset of approved testosterone products.
Safety in detail
Off-label SERM therapy for hypogonadism requires clinician evaluation and monitoring. Compounded enclomiphene is not FDA quality-assured.
What it does to fertility
Preserves or supports fertility by stimulating endogenous LH/FSH and spermatogenesis, the defining advantage over exogenous testosterone.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Total/free testosterone
- LH/FSH
- Estradiol
- Visual symptom review
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Class
- SERM (trans-isomer of clomiphene)
- Mechanism
- Raises endogenous testosterone via LH/FSH
- Fertility
- Generally preserved (vs suppressed by TRT)
- FDA status
- Not approved for hypogonadism (off-label)
- Sourcing
- Often compounded
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Enclomiphene as a Telehealth Product. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Enclomiphene (Androxal) trials2014-2016
Phase studies showed enclomiphene raised testosterone while maintaining sperm counts, unlike topical testosterone; FDA did not approve it for hypogonadism.